Oncogenomics handbook Book

Part I. Genomics, Cancer Targets, Transcriptomics, and Gene Expression Analysis

Genomic Resources for Cancer Biologists

Xuefeng Bruce Ling, Gene Cutler, and Timothy Hoey

Cancer Drug Target Identification by SAGE, LongSAGE, and Digital Karyotyping

Heiko Hermeking

Identification of Novel Cancer Target Antigens Utilizing EST and Genome Sequence Databases

Tapan K. Bera, Kristi A. Egland, B. K. Lee, and Ira Pastan

Tree-Based Cancer Classification and Diagnosis Using Gene Expression Data

Heping Zhang

From FISH to Proteomics: A Molecular Brush to Define Antitumor Drug Action

Balanehru Subramanian, Alexander Nakeff, and Frederick Valeriote

Gene Program Signatures for Papillomavirus E2-Mediated Senescence in Cervical Cancer Cells: Finding the Points of No Return

Sarah S. Williams, Bruce J. Aronow, and Susanne I. Wells

Part II. Advances in Proteomic and Enzymatic Cancer-Profiling Technologies

Mass-Spectrometry-Based Proteomics for Cancer Biology

Chen Xu and John R. Yates III

Chemical Proteomics in Drug Development

Douglas A. Jeffery, Amos Baruch, and Matthew Bogyo

Proteomics-Based Anticancer Drug Discovery

K. K. Jain

Cancer Metabolic Phenotype: Exploiting the Cancer Metabolome in Drug Discovery

John R. Griffiths and Marion Stubbs

Focusing Target Discovery and Validation Through Proteogenomics and Molecular Imaging

Lucy A. Carver and Jan E. Schnitzer

Part III. Cancer Target Validation: Cellular Approaches

RNA Interference: RNAid for Future Therapeutics?

Mustapha Diallo, Katja Schmitz, and Ute Schepers

Image-Based Assays of Cellular Phenotype for Drug Target Discovery and Validation

Kris F. Sachsenmeier and Jonathan A. Terrett

Targeting Inducible Chemotherapy Resistance Mechanisms in Colon Cancer

David Ljungman and James C. Cusack, Jr.

Targeting Apoptosis Pathways for Cancer Therapy

Bharvin K. R. Patel

Part IV. Cancer Target Validation: Animal Approaches

Genetically Engineered Mouse Models of Human Cancer for Drug Discovery and Development

Rónán C. O'Hagan, Min Wu, William M. Rideout III, Yinghui Zhou, and Joerg Heyer

Unraveling the Complexity of Oncogenesis Through In Vivo Optical Imaging

Pamela Reilly Contag

Innovative Strategies for Improving Engineered Mouse Models of Human Cancer for Preclinical Development

Jeffrey J. Martino and Suzie Chen

Use of Adenovirus-Mediated Gene Transfer to Facilitate Biological Annotation of Novel Genes

Jeff L. Ellsworth, Andrew Feldhaus, and Steven D. Hughes

Cancer Biology and Transgenic Technology in the Mouse: Bridging the Functional Gap

Cindy E. McKinney and Cooduvalli S. Shashikant

Homology-Based Genomic Mining of Growth Factors Implicated in Neoplasia and Nephritides: PDGF-D

Gary C. Starling, William J. LaRochelle, and Gulshan Ara

Part V. Cancer Prognostics, Diagnostics, and Biomarkers

Cancer Pharmacogenomics: Predicting Drug Response in the Genomic Era

Brian Z. Ring and Huijun Z. Ring

Diagnosis and Treatment of Malignancies Using Gene Expression Profiling

Jimmy C. Sung, Alice Y. Lee, and Timothy J. Yeatman

Implications of Epigenetics for Early Cancer Diagnosis and Prevention

Mukesh Verma and Sudhir Srivastava

Novel Molecular and Genetic Prognostic Biomarkers in Prostate Cancer

Arnab Chakravarti and Gary Guotang Zhai

PSA in Prostate Cancer Diagnosis

Pradip Datta

Tumor Targets and Biomarkers in Renal Cell Carcinoma

Ivar Bleumer and Peter F. A. Mulders

Part VI. Emerging Approaches to Cancer Therapy

VI-A. Targeting the Vasculature

Tumor Vasculature as a Target for Cancer Therapy

Grzegorz Korpanty, Xianming Huang, and Rolf A. Brekken

Targeting the VEGF/VEGFR Axis for Cancer Therapy

Frank A. Scappaticci

Inhibiting Cancer Angiogenesis With Molecular Therapy

Qixin Leng and A. James Mixson

VI-B. Supportive and Adjuvant Therapies

Development of Palifermin (rHuKGF) for Mucositis

Ping Wei and Catherine L. Farrell

Immune Modulation: The B7 Family Cosignaling Molecules as Emerging Targets for Enhancing Cancer Therapy

Sheng Yao and Lieping Chen

VI-C. Tumor-Targeted Therapies

Proteasome Inhibition and Its Clinical Application in Solid Tumors

David J. Park and Heinz-Josef Lenz

Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy

Anas Younes and Andrea Cerutti

Small-Molecule Receptor Tyrosine Kinase Inhibitors in Targeted Cancer Therapy

Carlos García-Echeverría

The mTOR Pathway and Its Inhibitors

John B. Easton and Peter J. Houghton

Cyclo-Oxygenase-2 Enzyme and Its Inhibition in Tumor Growth and Therapy

Zhongxing Liao, Uma Raju, Kathryn A. Mason, and Luka Milas

Understanding Prostate-Specific Membrane Antigen and Its Implication in Prostate Cancer

Arundhati Ghosh and Warren D. W. Heston

Development of a Radiolabeled Monoclonal Antibody to Prostate-Specific Membrane Antigen

Stanley J. Goldsmith, Shankar Vallabhajosula, Matthew I. Milowsky, David M. Nanus, Lale Kostakoglu, and Neil H. Bander

Monoclonal Antibody Strategies for Targeting HER2

Joan Albanell, Jeffrey S. Ross, Linda Pronk, and Pere Gascon

From XenoMouse® Technology to Panitumumab (ABX-EGF)

Xiaodong Yang, Lorin Roskos, C. Geoffrey Davis, and Gisela Schwab

Development and Evaluation of Cancer Therapeutic Agents Targeting TRAIL Receptor 1 and 2

Robin C. Humphreys

Clinical Studies of Immunotherapy With Rituximab (Rituxan®) and Radioimmunotherapy With Ibritumomab Tiuxetan (Zevalin®) in B-Cell Lymphoid Malignancies

Arturo Molina

Part VII. Informatics Strategies and Initiatives

Informatics Strategies and Initiatives Used in Cancer Research

Martin D. Leach

Index